← Leaderboards
James Daniel Akula
Boston Children'S Hospital
$2,104,345
Attributed
$2,104,345
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $442.5K · FY2009–21$500K$375K$250K$125K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$2,104,345 · 2
By mechanism
R01$1,314,225 · 1
RC1$790,120 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Molecular”
- David Heimbrook · Leidos Biomedical Research, Inc.$871,088,761
- Leonard Freedman · Leidos Biomedical Research, Inc.$468,573,385
- Richard Webby · St. Jude Children'S Research Hospital$254,843,170
- Larry Arthur$238,531,074
- Gregory H Reaman · National Childhood Cancer Foundation$230,630,913
- Ralph Parchment · Leidos Biomedical Research, Inc.$193,231,914
Research focus
MolecularRetinopathy Of PrematurityImageMetabolismPhotoreceptorsRetinal NeuronChildhoodHigh RiskInfantMetabolicOxygenPathologic NeovascularizationBaseRattusAcuteBlood VesselsFunctional DisorderGrowth FactorChildBlindBlindnessLightNeural RetinaSeverities
Grant awards (5)
Noninvasive Protection Against Retinopathy of Prematurity$429,225
R01 · FY2021 · EY · contact PI
Noninvasive Protection Against Retinopathy of Prematurity$442,500
R01 · FY2020 · EY · contact PI
Noninvasive Protection Against Retinopathy of Prematurity$442,500
R01 · FY2019 · EY · contact PI
Downregulation of Rod Metabolism in Retinopathy of Prematurity$387,741
RC1 · FY2010 · EY · contact PI
Downregulation of Rod Metabolism in Retinopathy of Prematurity$402,379
RC1 · FY2009 · EY · contact PI